This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

12 Jul 2021

LGM Pharma launches analytical and stability testing as standalone service

The integrated CDMO rolls out services to the broader community of drug manufacturers and developers

LGM Pharma, a company offering integrated CDMO services, is launching its analytical services and facilities as a standalone contract service for drug developers and manufacturers.

The decision comes after the company's acquisition of Nexgen Pharma's formulation development and drug product contract manufacturing business last year, which LGM Pharma said "significantly expanded" its physical infrastructure and talent.

The additional 100,000 sq. ft of specialised facilities, equipment and 150 experienced staff with expertise in analytical and stability testing, along with expertise in all aspects of pharmaceutical finished product development and manufacturing, has placed LGM Pharma in a position to offer a full suite of these services as a standalone option.

The CDMO has a network of cGMP facilities in California, Colorado, and Texas, state-of-the-art chromatography and spectroscopy equipment, and more than 60 quality assurance, quality control and analytical staff members.

Mentioned Companies
LGM Pharma
View company profile

Related News